A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

Globally, there are more than 500,000 new infections with drug-resistant tuberculosis each year. In this trial involving patients with rifampin-resistant tuberculosis, a shorter, more intense course of treatment (9 to 11 months) was found to be noninferior to a standard 20-month regimen.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-03, Vol.380 (13), p.1201-1213
Hauptverfasser:	Nunn, Andrew J, Phillips, Patrick P.J, Meredith, Sarah K, Chiang, Chen-Yuan, Conradie, Francesca, Dalai, Doljinsuren, van Deun, Armand, Dat, Phan-Thuong, Lan, Ngoc, Master, Iqbal, Mebrahtu, Tesfamarium, Meressa, Daniel, Moodliar, Ronelle, Ngubane, Nosipho, Sanders, Karen, Squire, Stephen Bertel, Torrea, Gabriela, Tsogt, Bazarragchaa, Rusen, I.D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult AIDS-Related Opportunistic Infections - drug therapy AIDS-Related Opportunistic Infections - mortality Antibiotics Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Clinical trials Drug Administration Schedule Drug dosages Drug Therapy, Combination Female Fluoroquinolones HIV Human immunodeficiency virus Humans Intention to Treat Analysis Kaplan-Meier Estimate Male Medication Adherence Middle Aged Moxifloxacin Moxifloxacin - administration & dosage Moxifloxacin - adverse effects Multidrug resistance Multidrug resistant organisms Rifampin Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - mortality Tuberculosis, Pulmonary - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Globally, there are more than 500,000 new infections with drug-resistant tuberculosis each year. In this trial involving patients with rifampin-resistant tuberculosis, a shorter, more intense course of treatment (9 to 11 months) was found to be noninferior to a standard 20-month regimen.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1811867